Tolterodine for Treatment of Overactive Bladder

Urologic Clinics of North America

Volumn 33, Issue 4, 2006, Pages 447-453

  Kanofsky, Jamie A ^a   Nitti, Victor W ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE;

CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HEADACHE; HUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; URGE INCONTINENCE; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CRESOLS; DELAYED-ACTION PREPARATIONS; HUMANS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; URINARY BLADDER, OVERACTIVE;

EID: 33748979164     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2006.06.004     Document Type: Review

References (31)

1. Andersson K.-E. The overactive bladder: pharmacologic basis of drug treatment. Urology 50 Suppl 6A (1997) 74-84
2. Abrams P., Larsson G., Chapple C., et al. Factors involved in the success of antimuscarinic treatment. BJU Int 83 Suppl 2 (1999) 42-47
3. Yarker Y., Goa K.L., and Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6 (1995) 243-262
4. Thuroff J., Bunke B., Ebner A., et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency, and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145 (1991) 813-817
5. Appell R.A., Abrams P., Drutz H.P., et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 19 (2001) 141-147
6. Van Kerrebroeck P., Kreder K., Jonas U., et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57 (2001) 414-421
7. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 11 (2000) 13-27
8. Stahl M.M.S., Eckstrom B., Sparf A., et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 14 (1995) 647-655
9. Appell R. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 50 Suppl 6A (1997) 90-96
10. Abrams P., Freeman R., Anderstrom C., et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81 6 (1998) 801-810
11. Drutz H.P., Appell R.A., Gleason D., et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogyn J 10 5 (1999) 283-289
12. Chapple C.R., and Nilvebrant L. Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs R D 3 2 (2002) 75-81
13. Todorova A., Vonderheid-Guth B., and Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41 (2001) 636-644
14. Postlind H., Danielson A., Lindgren A., et al. Tolterodine, a novel muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 26 4 (1998) 289-293
15. Brynne N., Dalen P., Alvan G., et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 63 5 (1998) 529-539
16. Hills C.J., Winter S.A., and Balfour J.A. Tolterodine. Drugs 55 (1998) 813-820
17. Clemett D., and Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 18 4 (2001) 277-304
18. Brynne N., Stahl M.M.S., Hallen B., et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 35 (1997) 287-295
19. Olsson B., Brynne N., and Johansson C. Food increases the bioavailability of tolterodine but not effective exposure. J Clin Pharmacol 41 3 (2001) 298-304
20. Rovner E.S., and Wein A.J. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 41 (2002) 6-14
21. Olsson B., and Szamosi J. Multiple-dose pharmacokinetics of a new once-daily, extended-release tolterodine formulation versus immediate-release tolterodine. Clin Pharmacokinet 40 3 (2001) 227-235
22. Olsson B., and Szamosi J. Food does not influence the pharmacokinetics of a new, extended-release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 40 2 (2001) 135-143
23. Nilvebrant L., Andersson K.-E., Gillberg P.-G., et al. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharm 327 (1997) 195-207
24. Nilvebrant L., Hallen B., and Larsson G. Tolterodine: a new bladder selective, muscarinic receptor antagonist: pre-clinical pharmacological and clinical data. Life Sci 60 (1997) 1129-1136
25. Nilvebrant L., Gillberg P.-G., and Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 81 (1997) 169-172
26. Nilvebrant L, Pahlman I, d'Argy R. Tissue distribution of tolterodine and its metabolites: low penetration into the central nervous system. Presented at the 15th Meeting of the European Association of Urology. Brussels, April 12-15, 2000.
27. Appell R.A., Sand P.K., Dmochowski R.R., et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 76 (2001) 358-363
28. Diokno A.C., Appell R.A., Sand P.K., et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78 (2003) 687-695
29. Sussman D., and Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Cur Med Res Opin 18 (2002) 177-184
30. Coyne KS, Matza LS, Kopp Z, et al. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 Jan 24 [Epub ahead of print].
31. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48 (2005) 464-470